Fox Run Management L.L.C. Has $1.28 Million Stock Holdings in Cellebrite DI Ltd. $CLBT

Fox Run Management L.L.C. grew its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 293.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 70,742 shares of the company’s stock after acquiring an additional 52,756 shares during the period. Fox Run Management L.L.C.’s holdings in Cellebrite DI were worth $1,275,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in CLBT. Cooper Creek Partners Management LLC acquired a new stake in shares of Cellebrite DI during the 3rd quarter worth about $55,999,000. Granahan Investment Management LLC increased its position in shares of Cellebrite DI by 1,108.5% during the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock worth $48,721,000 after purchasing an additional 2,411,726 shares in the last quarter. Capital International Investors acquired a new stake in shares of Cellebrite DI during the 4th quarter worth about $41,073,000. Invesco Ltd. increased its position in shares of Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares in the last quarter. Finally, Pertento Partners LLP increased its position in shares of Cellebrite DI by 57.8% during the 3rd quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after purchasing an additional 1,702,574 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Insider Buying and Selling

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This represents a 2.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 13,269 shares of company stock worth $169,592. 5.70% of the stock is owned by corporate insiders.

Cellebrite DI Stock Down 3.4%

Shares of NASDAQ:CLBT opened at $12.98 on Wednesday. Cellebrite DI Ltd. has a 12 month low of $11.02 and a 12 month high of $19.98. The company’s 50-day moving average price is $13.27 and its two-hundred day moving average price is $15.12. The firm has a market cap of $3.24 billion, a P/E ratio of 46.36, a P/E/G ratio of 1.66 and a beta of 1.17.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CLBT. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. DA Davidson began coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 target price for the company. Finally, Needham & Company LLC dropped their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.